Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

ClinicalTrials.gov ID: NCT07029828

Public ClinicalTrials.gov record NCT07029828. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 12:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.

Study identification

NCT ID
NCT07029828
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
140 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 14 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 9, 2025
Primary completion
Jun 25, 2030
Completion
Jun 25, 2030
Last update posted
Apr 27, 2026

2025 – 2030

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
California Dermatology & Clinical Research Institute Encinitas California 92024 Recruiting
Pediatric Skin Research Miami Florida 33156 Recruiting
D&H Tamarac Research Center Tamarac Florida 33321 Not yet recruiting
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46250 Recruiting
Kindred Hair and Skin Center Marriottsville Maryland 21104 Not yet recruiting
Michigan Dermatology Institute Waterford Michigan 48328 Not yet recruiting
Ear, Nose & Throat Consultants, LLC Omaha Nebraska 68144 Recruiting
Skin Specialists, PC dba Schlessinger MD Omaha Nebraska 68144 Recruiting
Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) Papillion Nebraska 68046 Recruiting
University of New Mexico Health Sciences Center Albuquerque New Mexico 87102 Recruiting
University of New Mexico-IDS Pharmacy Albuquerque New Mexico 87106 Recruiting
Regents of the University of New Mexico Albuquerque New Mexico 87131 Recruiting
Equity Medical, LLC The Bronx New York 10455 Not yet recruiting
Northwest Dermatology Institute Portland Oregon 97210 Recruiting
Penn State Health Milton S. Hershey Medical Center Hershey Pennsylvania 17033 Not yet recruiting
Medical University of South Carolina Department of Dermatology and Dermatologic Surgery Charleston South Carolina 29425 Not yet recruiting
3A Research El Paso Texas 79902 Recruiting
Texas Dermatology and Laser Specialists San Antonio Texas 78218 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07029828, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07029828 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →